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plan in US covering 4 million lives. Outcomes measure was any occurrence of CV
including ischemic heart disease, cerebrovascular disease, and peripheral vascular 
disease. A multivariate logistic model was developed to evaluate adjusted CV-risk. 
Multicollinearity test and Hosemer-Lemeshow test were performed. RESULTS:
Mean(/SD) age was 57(/8) years in combo-group(N  53) and 57(/11) years
in mono-group(N  5670). In combo-group, mean(/SD) treatment-duration
was 779(/424) days for statinﬁ brate combination-therapy. In mono-group, 
mean(/SD) treatment-duration was 987(/588) days for statin-monotherapy. 
Unadjusted CV-rates of combo-group versus mono-group were not signiﬁ cantly dif-
ferent (odds ratio [OR]  1.39, P  0.2313). Although adjusting for age, gender, prior 
CV, CV related pharmacy-costs, total medical-costs, diabetes with complication, and 
Elixhauser-comorbidity, CV-rates of combo-group versus mono-group were not sig-
niﬁ cantly different (OR  1.186, P  0.5929). All covariates were signiﬁ cantly associ-
ated with CV-rates. The model did not suffer from multicollinearity and the model
goodness-of-ﬁ t was satisfactory (P  0.5575). CONCLUSIONS: In a managed care 
population with type-II diabetes after adjusting for known baseline differences, CV-
risks among subjects who used statinﬁ brate combination-therapy compared to those 
who used statin-monotherapy did not signiﬁ cantly differ. This is different from what 
people expected for the combination-therapy, due to low power resulting from small 
sample size for combo-group. We hope this result will be useful in health policy to
ﬁ nd treatment strategies to reduce CV-risk in diabetics. Future research is in progress
to address the causality behind this association.
PCV9
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OBJECTIVES: There is limited evidence of comparative effectiveness of individual
Angiotensin Converting Enzyme (ACE) inhibitors for treatment of heart failure. We 
compared the clinical effectiveness in patients with Chronic Heart Failure (CHF). 
METHODS: The study was a retrospective analysis of a national cohort of patients
diagnosed with CHF from October 1, 1996 through September 30, 2003 identiﬁ ed 
from the Department of Veterans Affairs electronic medical records system. The
independent variables of interest were individual ACE inhibitors treatment groups:
Benazepril, Captopril, Enalapril, Fosinopril, Lisinopril, Quinapril, and Ramipril. 
Outcome assessed was death within one year. Cox-proportional hazards analysis was
employed to assess the adjusted association between these treatments and mortality
within one year after controlling for demographic factors, duration of CHF, comor-
bidities and comedications. RESULTS: A total of 188,445 patients with CHF were
identiﬁ ed. Majority of the patients were males (94.74%) and whites (53.68%). Lisino-
pril (71.93%) was the most commonly prescribed ACE Inhibitor followed by Fosino-
pril (20.90%) and Captopril (6.39%). In the multivariable model, Enalapril, adjusted
hazard ratio 0.715 (95% CI: 0.584 – 0.876), Fosinopril, adjusted hazard ratio 0.778 
(95% CI: 0.729–0.830), and Lisinopril 0.784 (95% 0.740–0.831) were found to have 
a statistically signiﬁ cant protective effect as compared to Captopril (referent group). 
Benazepril, Ramipril, and Quinapril were not statistically signiﬁ cantly different from 
Captopril effect. CONCLUSIONS: Enalapril, Fosinopril and Lisinopril were associ-
ated with signiﬁ cantly reduced risk of death within one year. Further research is needed 
to examine other outcomes including cost-effectiveness of ACE inhibitor use in the 
treatment of heart failure.
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OBJECTIVES: There is limited evidence of comparative effectiveness of Angiotensin 
Receptor Blockers (ARBs) for the treatment of Chronic Heart Failure (CHF). We 
compared the clinical effectiveness of Losartan, Valsartan,Candesartan, Telmisartan
and Irbesartan in patients with CHF. METHODS: The study was a retrospective 
cohort study utilizing national Veterans Affairs electronic medical records. The cohort 
consisted of all heart failure patients diagnosed between October 1, 1997 to September
30, 2002. After excluding patients with any exposure to ARBs within the previous 6
months, new exposure to ARBs was determined between the index date (October 1, 
2000) and the study end date (September 30, 2002) and subsequent time to death was
measured concurrently during that period. Five treatment groups were deﬁ ned based
on initial use of: Candesartan, Valsartan, Losartan, Irbesartan, and Telmisartan.
Multiple Cox proportional hazards regression analysis was employed to assess the
adjusted association between these treatments and time to death after controlling for 
demographics, hospitalization, years with CHF, 30 comorbidities and comedications.
Losartan was chosen as the reference drug because it was the ﬁ rst ARB introduced 
into the market. RESULTS: Total 19,186 patients were identiﬁ ed. Majority of the 
patients were male (98.06%).The most common comorbid condition in the cohort 
was hypertension(81.17%) followed by Ischemic Heart Disease(68.65%) and diabe-
tes(48.46%). Irbesartan (55.50%) was the most commonly prescribed ARB followed 
by Losartan (19.44%). In the multivariable model losartan was found to have a sta-
tistically signiﬁ cant decreased risk as compared to telmisartan, adjusted hazard ratio 
for telmisartan was 1.66 (95% CI: 1.12 – 2.46).Irbesartan, Valsartan, and Candesar-
tan were not statistically signiﬁ cantly different from Losartan. CONCLUSIONS: All
of the ARBs had similar associations with time to death, except telmisartan, which
had a statistically increased risk of mortality within two years. Further research is 
needed to examine other outcomes including cost-effectiveness in the treatment of 
heart failure.
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OBJECTIVES: To assess the clinical effectiveness of point-of-care (POC) INR monitor-
ing devices for patient on long-term oral anticoagulation therapy (OAT). METHODS:
A systematic review of the clinical literature was performed. Seventeen RCT studies 
published between January 1996 and November 2008 comparing POC devices to
routine anticoagulation control were included in the analysis. RESULTS: Of the 17
studies included in the analysis, 15 studies compared patient self-management or self-
testing to routine anticoagulation control and 2 studies examined the use of POC 
devices by primary health care practitioners. There was variation among the studies
regarding observation periods, indication for OAT and overall study quality. Based
on pooled analyses, there was no signiﬁ cant difference in major hemorrhagic events 
between patients in POC monitoring groups and usual care controls (OR 0.77, 95% 
CI 0.54, 1.10). POC monitoring resulted in signiﬁ cantly fewer thromboembolic events
(OR 0.56, 95% CI 0.39, 0.80) and deaths (OR 0.63, 95% CI 0.41, 0.97) compared
with usual care. Subgroup analyses included POC strategy, control strategy, indication 
for OAT, study quality, length of follow-up and industry sponsored. Mean time in the
therapeutic range was pooled across studies and weighted by the number of patient-
years of observation to assess INR control. The POC monitoring patients were in
range 68.6% of the time compared with 64.3% of time in usual care controls. Data 
were deemed unreliable to estimate 95% CI for pooled estimates. Higher testing fre-
quency and more intensive patient education in the POC monitoring groups may also 
partially explain observed differences in clinical outcomes. CONCLUSIONS: The 
review of clinical evidence suggest that using POC monitoring devices for patients on 
long-term OAT results in signiﬁ cantly fewer deaths and thromboembolic events and 
may result in better INR control than conventional laboratory testing. Nevertheless,
the use of POC devices should factor patient suitability, health system constraints and 
affordability.
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OBJECTIVES: Fondaparinux was shown to be non-inferior to enoxaparin in treat-
ment of deep vein thrombosis (DVT) in a clinical trial setting. Comparisons of out-
comes between these agents for treatment of DVT or pulmonary embolism (PE) in a 
naturalistic setting are not known. Objective of this study was to evaluate real-world 
economic outcomes of fondaparinux vs. enoxaparin for inpatient treatment of venous 
thromboemolism (VTE). METHODS: Retrospective analysis of discharge data from 
over 550 US acute care hospitals was conducted to evaluate and compare economic 
outcomes of patients receiving fondaparinux or enoxaparin for VTE treatment. Dis-
charges containing ICD-9 diagnosis codes for VTE (DVT, PE or both) were included.
Total hospital charges and index anticoagulant charges were captured for initial admis-
sion and any readmissions for VTE within 30-day follow-up. Demographic, clinical, 
and hospital descriptive measures were used to compare two treatment cohorts 
and to inform multivariate models. Expenditures in fondaparinux and enoxaparin 
cohorts were compared using a generalized linear methods (GLM) approach. 
RESULTS: Fondaparinux patients (n  366) were younger (61 vs. 64, p  0.001) 
than enoxaparin patients (n  14,674) and had more severe illness proﬁ les (APR DRG 
3.18 vs. 3.07, p  0.024). Average unadjusted charges for initial admission across 
the two groups were $76,352. Adjusted difference in charges for initial admission 
between fondaparinux and enoxaparin was not statistically signiﬁ cant (difference 
$574; p  0.906). Average unadjusted charges for overall study period including 30-
day follow-up were $80,764. Adjusted difference in charges between two groups was 
not statistically signiﬁ cant (difference  $3,633; p  0.536). Charges for index antico-
agulant during initial admission were $2233 for fondaparinux and $2497 for enoxa-
parin (p  0.108). After multivariate adjustment, this difference was signiﬁ cantly lower
in favor of fondaparinux (difference  $409, p  0.001). CONCLUSIONS: These 
real-world economic outcomes corroborate clinical trial ﬁ ndings supporting non-
inferiority of fondaparinux compared to enoxaparin for VTE treatment, as measured
by hospital charges. Further analyses of clinical outcomes in a naturalistic setting are 
warranted.
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OBJECTIVES: Untreated cholesterol increases with age. Furthermore, there are 
medical conditions requiring more aggressive lipid lowering, which become more 
prevalent with age; hence impacting the relationship between cholesterol and age. The
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objective was to study this relationship and determine whether it provides evidence
of lipid lowering therapy (LLT) effectiveness in European primary care. METHODS:
The study populations were identiﬁ ed from CSD Patient Data (France, Germany, Italy)
and THIN (UK) primary care databases. Included patients received lipid lowering 
prescription drugs in the ﬁ rst 6 months of 2005 (index) and had a prescription at least 
6 months before index. Cholesterol records within 12 months after index were 
obtained. Analyses were restricted to practitioners with cholesterol reporting rate
q50%. Multivariable linear regression was applied to evaluate the association between
cholesterol level and age controlling for gender, diabetes, cardiovascular disease,
hypertension, and LLT drug. RESULTS: In France, the median cholesterol was
5.23 mmol/L for age a65 (n  15537, 63% male) compared to 5.18 for age 65 (n 
16416, 46% male). In Germany, the median cholesterol was 5.26 mmol/L for age a65 
(n  4147, 63% male) compared to 5.10 for age 65 (n  6300, 48% male). In Italy,
the median cholesterol was 5.31 mmol/L for age a65 (n  2230, 59% male) compared
to 5.15 for age 65 (n  3232, 42% male). In the UK, the median cholesterol was 
4.50 mmol/L for age a65 (n  49,208, 61% male) compared to 4.30 for age 65 (n
 67,670, 50% male). For each country, cholesterol levels decreased with increasing
age (p  0.0001) controlling for covariates. CONCLUSIONS: This study presents 
population level evidence of LLT effectiveness in primary care as cholesterol levels did 
not increase with age, as would be expected in an untreated population. Furthermore, 
levels were lower among patients with conditions that warrant aggressive therapy
indicating LLT impact.
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OBJECTIVES: Examines the clinical and economic outcomes of this therapy modiﬁ ca-
tion in a community-based physician practice. Health care practitioners are commonly 
requested by insurers and patients to switch from their current statin to simvastatin
for cost reasons. METHODS: Medical record review via an electronic medical record
from a community-based primary care ofﬁ ce was performed on patients switched by
the physician from another statin to simvastatin between January 1, 2002 to October 
31, 2008. Patients were included if they had available lipid data pre- and post-switch.
National Cholesterol Education Program (NCEP) risk categories were calculated and
associated LDL cholesterol (LDL-C) goals assigned. Primary outcomes were changes
in lipid fractions and LDL-C goal attainment, analyzed by paired t-tests and McNe-
mar’s test, respectively. Economic outcomes were modeled using current retail medica-
tion prices and Medicare costs for medical services. RESULTS: A total of 48 patients
were identiﬁ ed; atorvastatin was the most common pre-switch statin (31 patients).
The cohort had a mean age of 64.612.6 years, was 60% female and 65% were
primary prevention. Over 95% of patients were switched to an appropriate equipotent 
dose of simvastatin. Mean pre-and post-switch LDL-C levels were 104 mg/dL and 
103 mg/dL, a non-signiﬁ cant reduction of 1.225.7 mg/dL (p  0.754). Results for the 
other lipid fractions and in a subanalysis of atorvastatin switched-patients showed
similar non-signiﬁ cant changes. A non-signiﬁ cant 4.1% increase in NCEP goal attain-
ment between the pre-switch (68.8%) and post-switch (72.9%) time periods was 
observed (p  0.754). Modeled cost savings were estimated at $575/patient/year.
CONCLUSIONS: Previously treated statin patients switched to equipotent doses of 
simvastatin achieved similar LDL-C lowering and NCEP goal attainment within this 
community-based, primary care setting. These results show the potential for signiﬁ cant 
cost savings for the health care system when appropriate patients are switched using
equipotent doses. Overall, these data support the approach that appropriate switching 
decisions should be made on a case-by-case basis.
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RANDOMIZED CONTROLLED TRIALS
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OBJECTIVES: Cholesterol-lowering treatment is known to reduce risk of coronary
heart disease independent of age and gender. However, the potential treatment effect 
difference of statin therapy between primary and secondary prevention trials has 
not been clearly demonstrated. This study aimed to estimate risk reduction of 
major coronary events, coronary mortality and total mortality associated with
statin drug treatment in primary and secondary prevention trials. METHODS:
Clinical trials conducted in human subjects and published in English-language journals
were collected by retrieving MEDLINE (1966–2008), bibliographies, and authors’ 
reference ﬁ les. Studies in which participants were randomized to statin or placebo for 
at least 4 years and coronary clinical disease or death was the primary outcome were 
included in the meta-analysis. RESULTS: Data from 4 primary and 4 secondary pre-
vention trials, with 46357 participants and 5.1 years treatment duration, were
included in this study. All patients in secondary preventions trials had a history of 
either myocardial infarction or angina. Meta-analysis revealed that statin drug treat-
ment reduced absolute risk for major coronary events per 1000 by 19 (P  0.001,
95% conﬁ dence interval [CI]: 9–29), 48 (P  0.001, 95% CI: 28–67) in primary and 
secondary prevention trials, respectively; by 3 (P  0.005, 95% CI: 1–5), 20 (P  0.001,
95% CI: 17–24) for coronary mortality; by 5 (P  0.043, 95% CI: 0–11), 25 (P 
0.001, 95% CI: 15–35) for all-cause mortality. Difference in coronary mortality and 
all-cause mortality between primary and secondary prevention trials was statistically 
signiﬁ cant since the CIs had nothing overlapped. CONCLUSIONS: This study indi-
cated that statin therapy provided a decrease in the risk of major coronary events, 
coronary mortality and all-cause mortality in both primary and second prevention 
trials; but the secondary prevention trials obtained considerably more events avoided 
due to treatment.
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OBJECTIVES: Episode Grouping is a methodology that enables health care profes-
sionals to analyze patient treatments and evaluate the quality of the treatments and 
manage the related costs. There are three procedures or treatments for a patient with 
coronary artery disease. Re-blocking an artery after a procedure directly affects the 
cost and severity of the treatment. We use statistic and probability method to examine
the information about patients with coronary artery disease and estimate the risk of 
re-blocking an artery after each procedure. METHODS: A dataset provided by an 
insurance company is used. It contained about 6,500,000 patient claims related to
year 2000–2005. Data processing is done by using SAS software and SAS codes. Then 
based on some assumptions and conditional probability the risk of re-blocking an
artery after each procedure (bare-stent, drug-eluting stent, and open bypass surgery) 
are estimated. RESULTS: Comparing the three types of procedures; bypass surgery,
drug-eluting stent, and bare stent, shows that the risk of re-blocking an artery after a 
bare stent is almost 24%, and by using the drug-eluting stent, this risk decreases to
almost 13%. Bypass surgery procedure has the lowest re-blocking rate that is less than 
7%. CONCLUSIONS: The Drug-eluting stent reduces the rate of re-blocking an artery 
to 46% compared to the bare stent. This is the main reason for shifting from the bare
stent to the drug-eluting stent and makes the drug-eluting stent more effective. But the 
rate of re-blocking after the drug-eluting stent is still about 6% more than the rate of 
re-blocking after an open bypass surgery. The main question remaining is how we 
can estimate the severity and quality of life after each procedure and justify the cost-
effectiveness of one of this procedure.
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OBJECTIVES: To determine the association between pharmacy treatments (ACE
Inhibitors (ACEI), Beta-blockers (BB)) and outcomes in patients with chronic heart
failure (CHF). METHODS: National retrospective cohort of Veterans Affairs (VA) 
patients, with at least one outpatient claim of CHF between October 1, 1996 and
September 30, 2001 (end of FY01), was identiﬁ ed. Exposure and outcomes were 
assessed in FY 2001 and FY 2002, respectively. ACEI/BB therapy was deﬁ ned as 
patients taking ACEI/BB with MPR (Medication Possession Ratio) 0.8 in exposure 
period. Outcomes were hospitalizations (all cause and heart failure) and total 
costs (inpatient, outpatient and pharmacy costs). Multivariate regression analysis 
was employed to determine outcome estimates; adjusted for socio-demographics, 
30 co-morbidities, co-medications and disease severity as measured by years with
heart failure. RESULTS: Total cohort comprised of 230,406 patients with mean 
age 69.96 o 10.39 years, 98% were men and 48% were whites. Of the total
cohort 89,757 (38.96%) were on ACEI therapy and 67,348 (29.23%) on BB therapy. 
Hypertension was the most prevalent comorbidity (78.76%). For all cause hospitaliza-
tion, BB was associated with 3.1% reduced risk (Adjusted OR: 0.969, 95% CI: 
0.944–0.994), whereas ACEI did not show any signiﬁ cant change (Adjusted OR: 1.0, 
95% CI: 0.98–1.029). For HF hospitalizations, BB reduced risk by 14.3% (Adjusted 
OR: 0.857, 95% CI: 0.812–0.904), whereas ACEI showed increased risk (Adjusted 
OR: 1.082, 95% CI: 1.029–1.137). Both therapies were associated with signiﬁ cant 
increase in costs compared to patients not receiving these medications (ACEI 5.3%, 
p  0.0001; BB 7%, p  0.0001). CONCLUSIONS: BB was associated with signiﬁ -
cantly reduced risk of all cause and HF hospitalizations, while ACEI did not show 
signiﬁ cant protective effect. Both therapies were found to increase total costs, suggest-
ing the need for more studies to examine cost-effective therapies for patients in routine 
clinical settings.
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OBJECTIVES: Statin medications are recommended for patients who have not 
achieved LDL-C goals through lifestyle modiﬁ cations. Little information exists regard-
ing the use of statins and LDL-C goal attainment among employed populations. This 
retrospective, observational study examined the statin medication usage pattern and 
the relationship between statin usage and LDL-C goal levels (according to ATP III 
guidelines) among a cohort of employees of a major ﬁ nancial services corporation.
METHODS: From 1995 to 2004, a total of 1,607 executives (average age 49.1, s.d. 
